Adamas to Present at Two Upcoming Investor Conferences

Tuesday, March 6, 2018 7:35 PM UTC

EMERYVILLE, Calif., March 06, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences:

Gregory T. Went, Ph.D., the company’s Founder, Chairman and Chief Executive Officer, is scheduled to present at the Cowen and Company 38^th Annual Health Care Conference on Monday, March 12, 2018 at 3:30 p.m. ET
Richard A. King, the company’s Chief Operating Officer, is scheduled to present at the 17^th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 9:00 a.m. ET

The presentations will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events.cfm. Archived versions of the webcasts will be available via replay for 30 days following the presentations.

About Adamas Pharmaceuticals, Inc.
Adamas is using its deep understanding of time-dependent biology to redefine the treatment experience for patients suffering from chronic neurological diseases. The company is building upon the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease, with a pipeline of differentiated investigational programs, which includes: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. Adamas’ goal is to create and commercialize a new generation of neurological medicines intended to lessen the burden of disease on patients, caregivers and society. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.

Contact:

Media:
Terri Clevenger
Continuum Health Communications
203-227-0209
[email protected]

Investors:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
[email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Adamas to Present at Two Upcoming Investor Conferences

Editor's Picks

Welcome to EconoTimes